Literature DB >> 7800783

Age-specific incidence of chickenpox.

R Finger1, J P Hughes, B J Meade, A R Pelletier, C T Palmer.   

Abstract

Because licensure of a chickenpox (varicella) vaccine is likely soon, it is important to ascertain the age-specific incidence of chickenpox. Increasing vaccine coverage and a resulting decrease in transmission may result in an accumulation of susceptible adults, followed by a shift of incidence into those older age groups in future years. Valid baseline age-specific incidence will make it possible to detect this phenomenon. Two studies were conducted in Kentucky to assess age-specific incidence of chickenpox. The first assessed chickenpox occurrence in two consecutive school-year cohorts of children from a geographically representative sample of Kentucky primary schools. The second gathered information from household members of those persons interviewed in the Behavioral Risk Factor Surveillance System telephone survey. The age-specific rates are remarkably similar between studies. Rates peak during the preschool and kindergarten years (ages 3-6). Approximately 20 percent of children remain susceptible to chickenpox after age 8 in both studies. The results from these two surveys will be valuable baselines for comparison with findings in incidence studies that will be performed after vaccine licensure.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7800783      PMCID: PMC1403576     

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  10 in total

1.  The risk of zoster after varicella vaccination in children with leukemia.

Authors:  R Lawrence; A A Gershon; R Holzman; S P Steinberg
Journal:  N Engl J Med       Date:  1988-03-03       Impact factor: 91.245

Review 2.  Varicella: complications and costs.

Authors:  S R Preblud
Journal:  Pediatrics       Date:  1986-10       Impact factor: 7.124

3.  Application of a live varicella vaccine in children with acute leukemia or other malignant diseases.

Authors:  T Izawa; T Ihara; A Hattori; T Iwasa; H Kamiya; M Sakurai; M Takahashi
Journal:  Pediatrics       Date:  1977-12       Impact factor: 7.124

4.  Population-based studies of varicella complications.

Authors:  H A Guess; D D Broughton; L J Melton; L T Kurland
Journal:  Pediatrics       Date:  1986-10       Impact factor: 7.124

5.  Mandatory reporting of infectious diseases by clinicians.

Authors:  T L Chorba; R L Berkelman; S K Safford; N P Gibbs; H F Hull
Journal:  JAMA       Date:  1989-12-01       Impact factor: 56.272

6.  Varicella zoster in hospital personnel: skin test reactivity to monitor susceptibility.

Authors:  R W Steele; M A Coleman; M Fiser; R W Bradsher
Journal:  Pediatrics       Date:  1982-10       Impact factor: 7.124

7.  Age-specific risks of varicella complications.

Authors:  S R Preblud
Journal:  Pediatrics       Date:  1981-07       Impact factor: 7.124

8.  Live attenuated varicella vaccine use in immunocompromised children and adults.

Authors:  A A Gershon; S P Steinberg; L Gelb
Journal:  Pediatrics       Date:  1986-10       Impact factor: 7.124

9.  Design, characteristics, and usefulness of state-based behavioral risk factor surveillance: 1981-87.

Authors:  P L Remington; M Y Smith; D F Williamson; R F Anda; E M Gentry; G C Hogelin
Journal:  Public Health Rep       Date:  1988 Jul-Aug       Impact factor: 2.792

10.  Live attenuated varicella virus vaccine. Efficacy trial in healthy children.

Authors:  R E Weibel; B J Neff; B J Kuter; H A Guess; C A Rothenberger; A J Fitzgerald; K A Connor; A A McLean; M R Hilleman; E B Buynak
Journal:  N Engl J Med       Date:  1984-05-31       Impact factor: 91.245

  10 in total
  7 in total

1.  Varicella vaccination for grades 4 and 5 students: from theory to practice.

Authors:  Paul Rivest; Lise Grenier; Guy Lonergan; Lucie Bédard
Journal:  Can J Public Health       Date:  2005 May-Jun

2.  Varicella susceptibility in a Canadian population.

Authors:  S Ratnam
Journal:  Can J Infect Dis       Date:  2000-09

Review 3.  Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency.

Authors:  Niklaus H Mueller; Donald H Gilden; Randall J Cohrs; Ravi Mahalingam; Maria A Nagel
Journal:  Neurol Clin       Date:  2008-08       Impact factor: 3.806

4.  The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003.

Authors:  W Katherine Yih; Daniel R Brooks; Susan M Lett; Aisha O Jumaan; Zi Zhang; Karen M Clements; Jane F Seward
Journal:  BMC Public Health       Date:  2005-06-16       Impact factor: 3.295

5.  Environmental chemical exposures and risk of herpes zoster.

Authors:  V Arndt; M F Vine; K Weigle
Journal:  Environ Health Perspect       Date:  1999-10       Impact factor: 9.031

6.  Cost-effectiveness of Varicella Vaccination Program in Iran.

Authors:  Shooka Esmaeeli; Mohsen Yaghoubi; Marzieh Nojomi
Journal:  Int J Prev Med       Date:  2017-12-05

7.  Impact of seasonal influenza on polyclinic attendances for upper respiratory tract infections in Singapore.

Authors:  Annabel C Y Soh; Anurag Sharma; David J Muscatello
Journal:  Western Pac Surveill Response J       Date:  2020-06-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.